IO Biotech said on Monday its experimental combination vaccine for a type of skin cancer helped slow the disease's ...

Cylembio did not meet its primary endpoint of progression-free survival (PFS), but did demonstrate a trend towards ...

IO Biotech’s cancer vaccine has “narrowly” failed to beat Merck's blockbuster oncology drug Keytruda in a phase 3 melanoma ...

A regimen involving the company’s shot failed a Phase 3 trial “by a hair,” an executive said, leading the company to believe ...

Shares of IO Biotech fell after the company said a cancer vaccine narrowly missed statistical significance on a Phase 3 study's primary endpoint. The stock was down 36%, to $1.15, late Monday ...

This week in health news, activist investor Engine Capital urges Avantor's board overhaul, China's Ab&B Bio-Tech IPO sees ...

IO Biotech's Phase 3 trial showed Cylembio plus Keytruda improved progression-free survival in advanced melanoma across most ...

IO Biotech (NASDAQ:IOBT) stock gained 6.1% after revealing topline data from its pivotal Phase 3 trial evaluating Cylembio, ...

IO Biotech (IOBT) stock rallies as cancer vaccine, Cylembio, with Merck's (MRK) Keytruda outperforms in a late-stage trial ...

Denmark-based IO Biotech’s shares traded 51% higher ahead of the morning bell at $2.74 after the company said that Cylembio ...

The Copenhagen-based company on Monday said top-line results from the phase 3 trial of its investigational, immune-modulatory, off-the-shelf therapeutic cancer vaccine, Cylembio, demonstrated clinical ...

IO Biotech said on Monday its experimental cancer vaccine, in combination with Merck's Keytruda, showed improvement in a late ...